Company profile: Roquefort Therapeutics
1.1 - Company Overview
Company description
- Provider of pre-clinical anti-cancer therapeutics, including Midkine-targeting antibodies; antisense oligonucleotides to reduce Midkine in cancer cells; gene-editing RNA and mRNA therapies for solid tumors; STAT-6 siRNA therapeutics; and MK cell therapy with direct and NK cell-mediated action, advancing candidates toward clinical trials.
Products and services
- MK Cell Therapy: Pre-clinical cell therapy delivering direct and NK cell-mediated anti-cancer action, developed within company programs and included as part of pre-clinical development efforts
- Midkine Antibodies: Pre-clinical anti-cancer antibodies targeting Midkine, showing efficacy in models of metastatic tumors and currently undergoing development for entry into clinical trials
- Midkine mRNA Therapeutics: Novel mRNA therapeutics targeting Midkine for solid tumors, developed internally to expand the company's anti-cancer portfolio
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Roquefort Therapeutics
AbbVie
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies and precision medicine across immunology, oncology, neuroscience, virology, and aesthetics. Offers HUMIRA for autoimmune conditions, IMBRUVICA for certain cancers, and RINVOQ for inflammatory diseases. Delivers genomics research and the AbbVie R&D Convergence Hub (ARCH) to integrate data and advance personalized drug discovery and treatment insights.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full AbbVie company profile →
Regeneron
HQ: United States
Website
- Description: Provider of innovative medicines, including EYLEA for eye diseases (age-related macular degeneration, diabetic retinopathy); Dupixent for atopic dermatitis, asthma and chronic rhinosinusitis with nasal polyposis; REGEN-COV for COVID-19; Libtayo for certain skin cancers and non-small cell lung cancer; Praluent to lower LDL cholesterol; and Kevzara for rheumatoid arthritis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Regeneron company profile →
Restorbio
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapeutics, focused on developing and commercializing novel treatments, including RTB101, a TORC1 inhibitor for aging-related diseases such as Parkinson’s disease.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Restorbio company profile →
Nurix Therapeutics
HQ: United States
Website
- Description: Provider of small molecule therapeutics and discovery via the DELigase platform leveraging E3 ligases and DNA-encoded libraries for targeted protein degradation (TPD) and elevation (TPE). Pipeline includes oral candidates NX-5948 (BTK degrader), NX-2127 (BTK/IKZF1/IKZF3 degrader), and NX-1607 (CBL-B inhibitor) for B-cell malignancies, solid tumors, and autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nurix Therapeutics company profile →
TargeGen
HQ: United States
Website
- Description: Provider of vascular biology-focused small molecule kinase inhibitors targeting vascular leakage (edema), vascular proliferation (angiogenesis), and inflammation, offering treatments for human diseases such as heart attack, cancer, and eye diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TargeGen company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Roquefort Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Roquefort Therapeutics
2.2 - Growth funds investing in similar companies to Roquefort Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Roquefort Therapeutics
4.2 - Public trading comparable groups for Roquefort Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →